Clinical Trial Detail

NCT ID NCT01036087
Title Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Panitumumab + Abraxane + Carboplatin

Fluorouracil + Epirubicin + Cyclophosphamide

Age Groups: adult

Additional content available in CKB BOOST